Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests

Patricia A Deverka; Grace A Lin; Kathryn A Phillips

doi:10.1001/jama.2024.19084

Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests

JAMA. 2024 Sep 30. doi: 10.1001/jama.2024.19084. Online ahead of print.

Authors

Patricia A Deverka^{1

2}, Grace A Lin^{2

3}, Kathryn A Phillips^{2

3}

Affiliations

¹ Deverka Consulting, LLC, Durham, North Carolina.
² Center for Translational and Policy Research on Precision Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco.
³ Institute for Health Policy Studies, University of California, San Francisco.

PMID: 39348131
DOI: 10.1001/jama.2024.19084

No abstract available

Plain language summary

This Viewpoint discusses proactively preparing to make informed payer coverage decisions to help address current disparities in Alzheimer disease diagnosis and treatment.